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Abstract: Background: Previous research indicates that total cholesterol levels increase 
with age during young adulthood and middle age and decline with age later in life.  
This is attributed to changes in diet, body composition, medication use, physical activity, 
and hormone levels. In the current study we utilized data from the Framingham Heart 
Study Original Cohort to determine if variations in apolipoprotein E (APOE), a gene involved 
in regulating cholesterol homeostasis, influence trajectories of total cholesterol,  
HDL cholesterol, and total: HDL cholesterol ratio from midlife through late life.  
Methods: Cholesterol trajectories from midlife through late life were modeled using 
generalized additive mixed models and mixed-effects regression models. Results: APOE e2+ 
subjects had lower total cholesterol levels, higher HDL cholesterol levels, and lower total: 
HDL cholesterol ratios from midlife to late life compared to APOE e3 and APOE e4+ 
subjects. Statistically significant differences in life span cholesterol trajectories  
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according to gender and use of cholesterol-lowering medications were also detected.  
Conclusion: The findings from this research provide evidence that variations in APOE modify 
trajectories of serum cholesterol from midlife to late life. In order to efficiently modify 
cholesterol through the life span, it is important to take into account APOE allele status. 
Keywords: cholesterol; life span; aging; Apolipoprotein E 
 
1. Introduction 
There is a negative perception associated with cholesterol among the general public due to the 
frequently observed relationship between high cholesterol and adverse health events, such as heart 
attack and stroke [1]. This perception that cholesterol only has a negative impact on health is 
somewhat misguided because cholesterol is an essential molecule for healthy functioning of the human 
body. The liver is the primary source of cholesterol for the body [2], but animal-based food products 
such as meat, eggs, and cheese are also significant sources of cholesterol [3]. Cholesterol is necessary 
for maintaining the structural integrity of cell membranes [4] and is a precursor for hormones like 
testosterone and estrogen and vitamin D, as well as bile salts, which aid in digestion [5]. Cholesterol is 
transported in the bloodstream by combining with specialized proteins to form lipoproteins. Low density 
lipoproteins (LDL) and very-low density lipoproteins (VLDL) are more buoyant because they contain 
more cholesterol in relation to protein. LDL transports cholesterol from the liver through the 
bloodstream to be used by cells throughout the body [6], and VLDL transports triglycerides and 
cholesterol to cells to be used for energy [7]. The low-density lipoprotein receptor (LDLR) is 
responsible for regulating the absorption of cholesterol and triglycerides into the cell [8]. Once VLDL 
has transported the triglycerides to a cell, it is converted to LDL [9]. High density lipoproteins (HDL) 
contain more protein in relation to cholesterol and as a result travel more efficiently through the blood 
stream than LDL and VLDL. HDL cholesterol is commonly referred to as “good cholesterol” because 
of its role in reverse cholesterol transport in which excess cholesterol is carried back to the liver where 
it is broken down and excreted from the body by being converted into bile [10,11]. Total cholesterol is 
the sum of HDL, LDL, and VLDL cholesterol. The ratio of total cholesterol to HDL cholesterol is a 
commonly used measure of cholesterol in clinical settings because this measure has been found to be 
more accurate in predicting coronary heart disease than either total cholesterol levels or LDL 
cholesterol levels [12–14]. However, the accuracy of this ratio is questionable at the extreme ends of 
the total and LDL cholesterol distributions [15]. The National Cholesterol Education Program 
recommends that for adults, total cholesterol levels should not exceed 200 mg/dL, LDL cholesterol 
levels should not exceed 100 mg/dL; HDL cholesterol levels should be at least 40 mg/dL for men and 
50 mg/dL for women [16]. Based on data from the National Health and Nutrition Examination Survey, 
the percentage of adults between the ages of 40 and 74 with high LDL cholesterol levels has declined 
from 59% between 1976–1980 to 27% between 2007–2010 [17]. This decline is due largely to the 
increasing trend in the number of Americans who have been prescribed cholesterol-lowering 
medications during the same time period [17]. Maintaining healthy levels of cholesterol is still a 
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significant public health concern because adults with high LDL cholesterol levels or low HDL 
cholesterol levels are at a substantial risk for cardiovascular diseases [18]. 
1.1. Age Related Changes to Cholesterol 
Previous research indicates that total cholesterol levels and LDL cholesterol levels increase with 
age among young and middle age adults and decline with age later in life [19–24]. The relationship 
between age and HDL cholesterol levels is controversial, with some studies supporting a decrease in 
HDL cholesterol levels with age, while others have reported minimal change and even an increase in 
HDL cholesterol levels with age [22,23,25]. There are several factors that contribute to the age related 
changes in cholesterol. First, LDLR activity tends to decrease with age leading to an increase in 
circulating LDL as less LDL is absorbed by cells [26]. A decrease in the conversion of cholesterol to 
bile acid with advancing age also contributes to an increase in serum cholesterol with age [27].  
The most consistent predictors across studies for an increase in total cholesterol levels among young 
and middle aged adults are consuming a high fat diet [28,29] and weight gain [20,30]. The decline in 
total cholesterol levels among older adults has been observed to coincide with dietary changes [24], 
weight loss, a decrease in body fat, and the use of statins and other cholesterol-lowering medications [19]. 
Hormonal changes also contribute to the age related changes in cholesterol observed among women. 
Young and middle-aged women tend to have lower total cholesterol and higher HDL cholesterol 
compared to men, but these gender differences become less apparent with increasing age [31].  
As women age, total cholesterol levels increase and HDL cholesterol levels may decrease due to a 
decline in estrogen production preceding menopause [32,33]. Estrogen regulates cholesterol 
biosynthesis [34] and estrogen replacement therapy is an effective approach for maintaining a healthy 
cholesterol profile for women who are approaching or experiencing menopause [35,36]. Measures of 
socioeconomic status, health behaviors, and health characteristics are also associated with total 
cholesterol levels and HDL cholesterol levels. Low education and low income are associated with poor 
cardiovascular health [37] and higher total cholesterol [37,38]. These same studies report that adults 
with high educational attainment and high income also have higher HDL cholesterol levels [37,38]. 
Also, adults who smoke have lower HDL cholesterol levels compared to non-smokers [39].  
Finally, hypertensive adults have higher total cholesterol levels and lower HDL cholesterol levels 
compared to adults without hypertension [40].  
Previous studies have reported that the effect of age on cholesterol remains significant even after 
adjusting for changes in diet, physical activity and the use of statins and other lipid lowering 
medications [21] suggesting that additional factors contribute to the age related changes in cholesterol. 
Among these potential factors, we explore here variations in apolipoprotein E (APOE), a gene involved in 
regulating cholesterol homeostasis. 
1.2. Apolipoprotein E and Cholesterol 
Several genes encode proteins that are critical to the absorption, transport, and excretion of 
cholesterol [41,42]. One such gene is APOE. APOE is located on the long arm of chromosome  
19 (19q13.2) and includes three common alleles (e2, e3, and e4) resulting in six distinct genotypes. 
The allelic frequency of the APOE e2, e3, and e4 alleles among Caucasians is approximately 7%,  
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78%, and 15%, respectively [43]. The apoE protein is one of several proteins that transport cholesterol 
and triglycerides through the bloodstream as VLDL and is also involved in the conversion of VLDL to 
LDL cholesterol and the absorption of cholesterol by the small intestines [44]. While there is debate on 
if APOE genotypes effect the rate of cholesterol absorption [45,46] adults with the APOE e3/e3 
genotype tend to have lower total cholesterol than adults with either the APOE e3/e4 or APOE e4/e4 
genotypes, but higher total cholesterol compared to adults with either the APOE e2/e4, e2/e3 or e2/e2 
genotypes [47–49]. When environmental factors such as high body mass index (BMI), consuming a 
high calorie diet and high blood sugar levels are also present, adults with the APOE e2/e2 genotype are 
at an increased risk for type III hyperlipidemia [50], a condition characterized by abnormally  
high bloodstream concentrations of chylomicrons, which are another lipoprotein that transports 
triglycerides to cells [7].  
The observed relationship between APOE genotypes and serum cholesterol has led to considerable 
research on the relationship between APOE polymorphisms and diseases associated with high 
cholesterol. The APOE e4 allele is associated with an increased risk for cardiovascular diseases [51], 
including stroke [52], and coronary heart disease [53]. The APOE e4 allele is also an established risk 
factor for dementia, in particular Alzheimer’s disease (AD) [54], whereas as the APOE e2 allele is 
associated with a decreased risk for AD relative to the APOE e3 allele [55]. The consistent association 
between AD and APOE has contributed to research on the relationship between serum cholesterol 
levels and AD risk. Interestingly, the association between serum cholesterol and AD appears to depend 
upon the age in which cholesterol is measured. High total cholesterol levels during middle age are 
associated with an increased risk for AD during old age [56], but older adults with AD tend to have 
lower total cholesterol compared to non-demented older adults [57] and high cholesterol during old 
age is associated with a decreased risk for AD [58]. Further, Stewart et al. [59] observed in the 
Honolulu-Asia Aging Study that men who developed dementia exhibited a decline in total cholesterol, 
on average, 15 years before dementia diagnosis and maintained lower total cholesterol levels during 
this 15 year period than men who did not develop dementia. A plausible hypothesis for apparent age 
dependent relationship between serum cholesterol and dementia is that there are distinct differences in 
serum cholesterol levels from midlife through late life according to APOE allele status. This justifies 
research to examine if trajectories of serum cholesterol from midlife through late life differ according 
to APOE allele status.  
The apoE alleles clearly modulate cholesterol homeostasis as indicated by the differences in 
cholesterol concentrations among adults according to APOE genotypes. However, it is not clear how 
APOE polymorphisms influence the longitudinal trajectories of cholesterol from midlife through late 
life. Accordingly, the purpose of this study is to characterize the longitudinal trajectories of total 
cholesterol, HDL cholesterol, and total: HDL cholesterol ratio according to APOE e2, e3, and e4 allele 
status utilizing data from the Framingham Heart Study (FHS) Original Cohort. 
2. Methods 
2.1. Framingham Heart Study: Original Cohort  
The FHS is an ongoing prospective cohort study of residents from Framingham Massachusetts, 
United States, created with the goal of generating knowledge on the onset and progression of 
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cardiovascular diseases, as well as genetic and environmental risk factors for these diseases.  
The FHS Original Cohort was initiated in 1948 and includes adults who did not have a cardiovascular 
disease upon entry into the study [60]. A total of 5079 subjects between the ages of 28 and 74  
(mean age 44.2 years) completed a baseline clinical examination between 1948 and 1953.  
Thirty clinical examinations have been completed since 1948, and 141 subjects (mean age 92,  
range 88–102) attended the thirtieth clinical exam, which concluded in 2010. During each wave of data 
collection, subjects received an extensive physical examination, which included non-invasive tests 
(e.g., body composition, x-ray, and pulmonary function), lab tests (e.g., lipid and hormone levels),  
and a health history questionnaire to assess health behavior and the onset of any health conditions 
since the previous wave of data collection. DNA collection from living members of the FHS Original 
Cohort began in the 1980s and APOE genotype data is available for a total of 663 subjects.  
For the purposes of the current study, subjects were classified as APOE e2+ (e2/e2 or e2/e3 genotype), 
APOE e3 (e3/e3 genotype), or APOE e4+ (e3/e4 or e4/e4). Subjects with the APOE e2/e4 genotype  
(n = 11) were excluded from the final sample due to the low sample size and conflicting influence that 
the APOE e2 and APOE e4 alleles have on cholesterol levels. Because the purpose of this study was to 
examine cholesterol trajectories beginning in midlife, nine subjects that were not between 30  
and 55 years of age during the first clinical examination were excluded from the final sample.  
Finally, all subjects had two or more repeated measures for total cholesterol; 21 subjects who had 
fewer than two consecutive repeated measures for HDL cholesterol were excluded from the final 
sample. The final sample included 596 subjects.  
2.2. Measures of Serum Cholesterol 
Measures for total cholesterol and HDL cholesterol were collected from subjects of the FHS 
Original Cohort using standard laboratory procedures [61]. Fasting measures for total cholesterol were 
collected during twenty clinical examinations (1–11, 13–15, 20, 22, 24–27) and measures of HDL 
cholesterol were collected during ten clinical examinations (9–11, 15, 20, 22, 24–27). The ratio of total:  
HDL cholesterol was calculated by dividing the measure of total cholesterol by the measure of  
HDL cholesterol. The distributions for total: HDL ratios were highly right skewed and were 
normalized by log transformation. Serum LDL cholesterol was directly measured in the FHS during 
three clinical examinations (9–11). The Friedewald equation [62] can be used to estimate  
LDL cholesterol levels based on total cholesterol, HDL cholesterol, and triglyceride levels  
(LDL = total – HDL – triglycerides/5). This equation, however, should not be used when triglyceride 
levels are greater than 400 mg/dL [62] and underestimates LDL cholesterol levels when triglyceride 
levels exceed 200 mg/dL [63]. Triglyceride levels were measured during nine clinical examinations 
(7–11, 24–27), but for any given clinical examination over 25 percent of subjects included in the final 
sample did not have a recorded triglyceride measure. Furthermore, over 13 percent of subjects in  
each clinical examination had triglyceride levels over 200 mg/dL. In light of these limitations,  
LDL cholesterol levels were not included in this study.    
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2.3. Statistical Analysis 
The trajectories of total cholesterol levels, HDL cholesterol levels, and total: HDL cholesterol ratios 
from midlife through late life according to APOE allele status were modeled using generalized additive 
mixed models [64] (GAMM) implemented using the gamm4 package[65] in R version 3.1 GAMM are 
semi-parametric models that utilize a data-driven approach to model a non-linear relationship between 
dependent and independent variables as opposed to restriction to fully parametric polynomial terms. 
The general form of the GAMM used for this study is: = +  ( = 2+) +  ( = 3) +  ( = 4+) +  +   
where  is the value of cholesterol for the ith subject during the jth observation given the covariates 
included in the model (see Covariates), and bi is a subject-specific random effect that allows for the 
baseline value of cholesterol to vary for each subject. Xi is a k-length vector comprising the k time-
invariant covariates of subject i and  is a k-length vector of the fixed effects for the corresponding k 
covariates; xij is the age of the ith subject during the jth observation; se2, se3, and se4 are the allele-
specific smoothing functions for subjects who were APOE e2+, e3, and e4+, respectively, APOEi is 
the allele status for the ith subject; and I( ) is an indicator function equal to 1 when x is true and 0 
otherwise. The term  is the within-subject error term, which is the difference between the observed 
measure of cholesterol and the expected measure of cholesterol based on the model.  
The terms bi and  are assumed to be independent and randomly distributed with mean zero and 
variances of  and , respectively. The inclusion of three different smoothing functions (se2, se3,  
and se4) allows for the trajectories of cholesterol to vary according to APOE allele status.  
The smoothing function (thin plate regression splines) models the potentially non-linear trajectory  
of cholesterol with advancing age. An advantage of the thin plate regression spline function over other 
smoothing functions is that the number and placement of knots that control the flexibility of the model 
do not need to be specified [66]. The more knots included in the model, the better the model will fit the 
data, but this is at the risk of over fitting the data. Concerns of over fitting are addressed by adding a 
second derivative function on the penalty to the least squares fitting approach [66] providing a tradeoff 
between model fit and model smoothness [67]. A detailed description of how the thin plate regression 
spline balances the flexibility and fit of the model has been previously provided [67].  
Briefly, the thin plate regression spline estimates the smoothing function si by identifying the function 
 that minimizes the equation described below.  is the smoothing term that reflects the flexibility  
of the model | − f| +  ( ) 
where | − f| can be interpreted as the observed data values minus the values predicted from the 
model, squared; ( ) is the penalty function that controls f; and  is the smoothing parameter that 
controls the balance between the model fit and the smoothness of f.  
The estimated trajectories of total cholesterol levels, HDL cholesterol levels, and total: HDL cholesterol 
ratio were plotted along with point-wise 95% confidence intervals constructed by calculating the upper 
and lower bounds for each predicted measure of total cholesterol levels, HDL cholesterol levels,  
and total: HDL cholesterol ratio. This allowed for the trajectories of total cholesterol levels,  
HDL cholesterol levels and total: HDL ratio according to APOE allele status to be visually examined. 
The plots of the estimated trajectories for the adjusted models were obtained by predicting the average 
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values of serum cholesterol based on age and the values of the covariates included in the model.  
These trajectories represent the average trajectory of serum cholesterol according to APOE allele status 
controlling for the effects of the covariates. The degree to which the trajectories of cholesterol  
departed from linearity is reflected by the effective degrees of freedom (EDF) of the smoothing 
parameter ( ) [68]. The EDF provides a measure of a model’s flexibility and a smooth term with  
x EDF can be interpreted as an x degree polynomial term. An EDF of 1 indicates that the trajectory is 
linear and increasing values of EDF indicate greater degrees of non-linearity. Including the  
EDF values, aids in the interpretation of the estimated trajectories by providing a value for the 
smoothing function of the trajectory. Also, the potential effects of covariates on the estimated trajectories 
can be assessed based on the changes to the EDF values as covariates are added to the models.  
GAMM allow for between group comparisons to be made based on the 95% confidence intervals of 
each measure of serum cholesterol, but a challenge when using this method is assessing statistically 
significant differences in the estimated trajectories of serum cholesterol according to APOE allele 
status or other variable of interest. Since the EDF of the smooth term can be interpreted as an x degree 
polynomial, we used the EDF values obtained from the GAMM as estimates for polynomial terms in 
mixed-effects regression models [69]. This allowed us to produce evidence for statistically significant 
differences for the trajectories and aided in the interpretation of the estimated trajectories of serum 
cholesterol levels presented in the Figures 1–4. 
2.4. Covariates 
Data for several potential confounding variables were collected during each clinical examination 
using standard laboratory procedures and a medical history interview. An overview of the covariates 
included in the present analysis and the years in which they were collected is provided in Table 1. 
Covariates were selected according to those included in previous studies that examined longitudinal 
changes in serum cholesterol levels [20,21]. Also, certain covariates that have been identified as 
having an effect on serum cholesterol levels were included even if the covariate had not been shown to 
be associated with APOE allele status. Age during the baseline clinical examination was included as a 
covariate to differentiate between-subject from within-subject variability for the change in serum 
cholesterol with age. Educational attainment was initially recorded according to the following 
categories: (1) none, (2) fourth grade or less, (3) fifth, sixth or seventh grade, (4) completed grade 
school, (5) some high school, (6) graduated high school, (7) some college, (8) college graduate or 
(9) post graduate. For the purposes of this study, educational attainment was dichotomized according 
to receiving a high school (HS) degree (<HS or >HS). From clinical examination 7 through 21, 
subjects were asked if they were using cholesterol-lowering drugs, and it was not until clinical 
examination 22 that subjects were asked which type of medication they used (resins, niacin, fibrates,  
or statins). Since specific cholesterol-lowering medications were not assessed until the 22nd clinical 
examination, subjects were dichotomized as having reported ever using a cholesterol-lowering 
medication (yes/no). The age in which subjects first started using cholesterol-lowering medications 
was included as a covariate in a subsequent analysis to account for differences in the timing in which 
subjects started taking cholesterol-lowering medications. Also, an analysis limited to only women that 
controlled for the use of supplemental estrogen and age of menopause was also conducted.  
During the 1st through 14th clinical examinations, women were asked the age in which menses had 
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stopped for one year or more and the cause of cessation (natural, surgical, or other). The average age 
of menopause was 47.5 years (SD = 6.0, range = 23–57 years), but significant differences in the 
average age of menopause according to cause of cessation were detected (natural (n = 242) 49.9 years, 
SD = 3.4; surgery (n = 108) 42.3 years, SD = 7.1; other (n = 3) 41.7 years, SD = 7.6; F-value = 92.9,  
p < 0.01). Therefore, the cause of cessation of menses was included as a covariate in this analysis.  
The use of supplemental estrogen (oral, patch, or cream) was assessed during clinical exams 17–27. 
Subjects were dichotomized as having reported ever using supplemental estrogen (yes/no).  
Subjects were asked during clinical exams 2, 4, 7–15, and 17 if they were consuming a diet meant to 
control high cholesterol, diabetes, hypertension, weight, or other low calorie diet. Subjects were 
dichotomized as reported ever consuming a restricted diet (yes/no). Systolic blood pressure, diastolic 
blood pressure, height (inches) and weight (pounds) were collected during each clinical examination. 
Smoking status was assessed during clinical exams 4–27. Blood sugar levels were measured during 
clinical exams 1, 2, 4, 6, 8–23, 26 and 27. Body mass index (BMI) was calculated as (weight/height2) 
× 703. Smoking status [70], blood pressure [71], BMI [72] and blood sugar [73] have been observed to 
change with age. Therefore, we included measures for these covariates during the 1st clinical examination 
(representing midlife) and 15th clinical examination (representing late life). This accounted for potential 
changes in these variables from midlife to late life and limited the number of covariates included in each 
model since these variables were measured during almost all clinical examinations. The 1st clinical 
examination represented midlife because only subjects between the ages of 30–55 during this examination 
were included in the final sample. Smoking status during the 4th clinical examination was included as a 
covariate since smoking was not assessed during the 1st through 3rd clinical examinations.  
Only 12 subjects (2.0% of final sample) did not attend the 4th clinical examination. The average age of  
the subjects who did attend the 4th clinical examination was 44.3 years (range = 35–61). The 15th clinical 
examination was selected for late life because the average age of the final sample was 66.3 years  
(range = 58–83 years). These cut offs for midlife and late life are consistent with those used in previous 
studies [74,75]. A total of 570 subjects (95.6% of final sample) attended the 15th clinical examination. 
Covariate values for the 14th or 16th clinical examination were used for subjects who did not attend the 
15th clinical examination.  
3. Results 
3.1. Description of Framingham Heart Study: Original Cohort  
The descriptive characteristics of subjects of included in the final sample are provided in Table 2.  
The final sample included a total of 596 subjects, of which 61 were APOE e2+ (n = 4 e2/e2; n = 57 
e2/e3), 406 were APOE e3, and 129 were APOE e4+ (n = 5 e4/e4; n = 124 e3/e4). The final sample 
was predominantly female and the majority of subjects had a high school degree or less. There were no 
statistically significant differences in APOE allele status according to any of the characteristics listed 
in Table 2. Compared to women, men were more likely to be current smokers during midlife  
(men = 149 (65.1%), women = 135 (38.8%),  = 44.4, p < 0.01) and late life (men = 79 (33.3%), 
women = 74 (21.3%),  = 56.6, p <0.01), had high average BMI during midlife (men = 25.7 kg/m2, 
women = 24.7 kg/m2, t-value = −3.4, p < 0.01) and late life (men = 27.2 kg/m2,women = 26.5 kg/m2,  
t-value = –2.2, p = 0.03), higher average blood sugar during late life, but not midlife, (men = 95.7 mg/dL,  
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women = 91.7, t-value = –2.0, p < 0.05), higher average systolic blood pressure during midlife,  
but not late life, (men = 131.5 mmHg, women = 126.3 mmHg, t-value = −4.0, p < 0.01), and higher 
average diastolic blood pressure during midlife (men = 82.6 mmHg, women = 80.3 mmHg,  
t-value = −2.6, p = 0.01 ) and late life (men = 78.1 mmHg, women = 75.5 mmHg, t-value = –3.1, p = 0.02). 
3.2. Total Cholesterol Stratified by APOE Allele Status  
The unadjusted and adjusted trajectories of total cholesterol, HDL cholesterol, and total:  
HDL cholesterol ratio, according to APOE allele status, are presented in Figure 1. Solid lines  
represent the mean measures of serum cholesterol according to APOE status and the shaded regions 
represent the point-wise 95% confidence intervals for each estimated measure. The degree of  
non-linearity for the trajectories as reflected by the estimated EDF of the smoothing term, and the 
model fit by adjusted R2, which is interpreted as the proportion of total variance explained by the 
model with an adjustment for model complexity, are presented in Table 3. According to visual 
inspection, there were little to no differences in the unadjusted mean measures of total cholesterol, 
HDL cholesterol, and total: HDL cholesterol ratio as indicated by the overlap of the 95% confidence 
intervals. Inclusion of covariates to the models noticeably reduced the variability in estimated 
cholesterol trajectories as indicated by the 95% confidence intervals for each measure of cholesterol; 
however, trajectories of cholesterol did not substantially change once covariates were added to the 
models as indicated by the consistent EDF values of the smooth terms. The dramatic reduction in the 
95% confidence intervals for the adjusted models compared to the unadjusted models suggests that 
several factors account for the variability in serum cholesterol levels. Including covariates reduces the 
error variance of the model, which reduces the variability of the estimates of serum cholesterol. 
Total cholesterol trajectories for APOE e2+, e3, and e4+ subjects all followed similar non-linear 
trends based on the EDF values (Table 3. Significant differences according to APOE allele status were 
detected after controlling for the effects of age, gender, educational attainment, smoking status, BMI, 
systolic and diastolic blood pressure, blood sugar levels, restricted diet, and use of cholesterol-lowering 
medications (Figure 1. Subjects who were APOE e2+ maintained consistently lower total cholesterol 
from midlife through late life compared to APOE e3 and APOE e4+ subjects. APOE e3 and APOE e4+ 
subjects had similar trajectories for total cholesterol until 50 years of age, at which point APOE e3 
subjects displayed a decline in total cholesterol while total cholesterol in APOE e4+ subjects continued 
to increase until 60 years of age. The greatest difference in total cholesterol between APOE e3 and 
APOE e4+ subjects was at 60 years of age and the differences in total cholesterol between these two 
groups became less apparent with advancing age. A mixed-effects regression model that included 
linear through 7th order polynomial terms for age detected statistically significant differences  
in the interaction terms from APOE allele status and quadratic (F-value = 4.7, p < 0.01) and quartic 
(F-value = 8.2, p < 0.01) terms, while the cubic term approached statistical significance 
(F-value = 2.9, p = 0.06).  
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Table 1. Assessment of total cholesterol, HDL cholesterol, and selected covariates from the Framingham Heart Study Original Cohort. 
Measure Measure Collected 
Age * * * * * * * * * * * * * * * * * * * * * * * * * * * 
Weight * * * * * * * * * * * * * * * * * * * * * * * * * * * 
Height * * * * * * * * * * * * * * * * * * * * * * * * * * * 
Diastolic 
BP 
* * * * * * * * * * * * * * * * * * * * * * * * * * * 
Systolic 
BP 
* * * * * * * * * * * * * * * * * * * * * * * * * * * 
Smoking    * * * * * * * * * * * * * * * * * * * * * * * * 
Diet  *  *   * * * * * * * * *  *           
Estrogen 
use 
                * * * * * * * * * * * 
Menopause 
cause 
* * * * * * * * * * * * * *              
Menopause * * * * * * * * * * * * * *              
Cholesterol 
medications 
      * * * * * * * * * * * * * * * * * * * * * 
Sex *                           
Education *                           
Blood 
sugar 
* *  *  *  * * * * * * * * * * * * * * * *   * * 
HDL 
cholesterol 
        * * *    *     *  *  * * * * 
Total 
cholesterol 
* * * * * * * * * * *  * * *     *  *  * * * * 
Clinical 
Exam 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
Years 1948 1950 1952 1954 1956 1968 1960 1962 1964 1966 1968 1971 1972 1975 1977 1979 1981 1983 1985 1986 1988 1990 1992 1995 1997 1999 2001 
Notes: Subjects were evaluated every 2 years beginning in 1948. Clinical examination 27 was completed in 2003. 
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Figure 1. Cholesterol trajectories stratified according to APOE e2+, e3, and e4+ allele status. 
 
Notes: APOE e4+ includes subjects with e3/e4 or e4/e4 genotypes; e3 includes subjects with e3/e3 genotype; and e2+ includes subjects with e2/e2 or e2/e3 genotypes. 
Unadjusted cholesterol trajectories (row one) only included APOE allele status. Adjusted cholesterol trajectories (row two) controlled for the effects of age gender, 
educational attainment, smoking status, systolic and diastolic blood pressure, blood sugar, body mass index, restricted diet, and use of cholesterol-lowering medications. 
Unadjusted trajectories n = 596; adjusted trajectories n = 555. Abbreviations: HDL = high density lipoprotein; APOE = apolipoprotein E. 
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Figure 2. Cholesterol trajectories stratified according to history of using cholesterol-lowering medications, and APOE allele status adjusting 
for age of first using cholesterol-lowering medications. 
 
Notes: APOE e4+ includes subjects with e3/e4 or e4/e4 genotypes; e3 includes subjects with e3/e3 genotype; and e2+ includes subjects with e2/e2 or e2/e3 genotypes. 
Cholesterol trajectories stratified by use of cholesterol-lowering medications (row one) controlled for the effects of age, gender, educational attainment, smoking status, 
systolic and diastolic blood pressure, blood sugar, restricted diet, body mass index, and APOE allele status (n = 555). Cholesterol trajectories stratified according to APOE 
allele status (row two) controlled for the effects of age, gender, educational attainment, smoking status, systolic and diastolic blood pressure, blood sugar, restricted diet, 
body mass index, and age of first using cholesterol-lowering medications. These trajectories only included subjects who had a history of using cholesterol-lowering 
medications (n = 102). Abbreviations: HDL = high density lipoprotein; APOE = apolipoprotein E. 
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Figure 3. Cholesterol trajectories stratified according to gender, and APOE allele status adjusting for age of menopause, use of supplemental 
estrogen, and cause of menses cessation. 
 
Notes: APOE e4+ includes subjects with e3/e4 or e4/e4 genotypes; e3 includes subjects with e3/e3 genotype; and e2+ includes subjects with e2/e2 or e2/e3 genotypes. 
Cholesterol trajectories stratified according to gender (row one) controlled for the effects of age, educational attainment, smoking status, systolic and diastolic blood 
pressure, blood sugar, use of cholesterol-lowering medications, restricted diet, body mass index, and APOE allele status (n = 555). Adjusted model controlled for the 
effects of age, educational attainment, smoking status, systolic and diastolic blood pressure, blood sugar, body mass index, restricted diet, APOE allele status, age of 
menopause, use of supplemental estrogen, and cause of cessation of menses (n = 335). Abbreviations: HDL = high density lipoprotein; APOE = apolipoprotein E. 
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Figure 4. Cholesterol trajectories stratified according to longevity, and APOE allele status for subjects who lived beyond 80 years of age. 
 
Notes: APOE e4+ includes subjects with e3/e4 or e4/e4 genotypes; e3 includes subjects with e3/e3 genotype; and e2+ includes subjects with e2/e2 or e2/e3 genotypes.  
All models controlled for the effects of age, gender, educational attainment, smoking status, systolic and diastolic blood pressure, blood sugar, restricted diet, body mass 
index, and use of cholesterol-lowering medications. Longevity models (row 1) also controlled for the effects of APOE allele status Cholesterol trajectories according to 
longevity (n = 555); cholesterol trajectories according to APOE allele status (n = 430); Abbreviations: HDL = high density lipoprotein; APOE = apolipoprotein E.
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Table 2. Demographic characteristics of final sample (n = 596). 
Characteristic Value 
Avg. age, midlife (range, SD) 38.3 (30.0–55.0, 5.5) 
Gender, n (%)  
Men 242 (40.6) 
Women 354 (59.4) 
Educational attainment  
<High school 387 (66.2) 
>High school  198 (33.8) 
Smoking midlife, n (%), n = 577  
Non-smoker 282 (48.9) 
Former 11 (1.9) 
Current 284 (49.2) 
Smoking, late life, n (%), n = 585  
Non-smoker 231 (39.5) 
Former 201 (34.3) 
Current 153 (26.1) 
Use of cholesterol-lowering medications, n (%)  
No 487 (81.7) 
Yes 109 (18.3) 
* Avg. age cholesterol medication use (SD, range) 69.7 (45.0–88.0, 11.4)  
Avg. midlife blood sugar, mg/dL (SD, range), n = 590 79.4 (13.5, 51.0–173.0) 
Avg. late life blood sugar, mg/dL (SD, range), n = 584 93.3 (24.2, 52.0–326.0) 
Avg. midlife systolic blood pressure, mmHg (SD, range) 128.4 (16.0, 90.0–195.0) 
Avg. late life systolic blood pressure, mmHg (SD, range), n = 588 135.9 (19.5, 92.0–212) 
Avg. midlife diastolic blood pressure, mmHg (SD, range) 81.3 (10.4, 50.0–125.0) 
Avg. late life diastolic blood pressure, mmHg (SD, range), n = 588 76.6 (9.8, 50.0–104.0) 
Avg. midlife body mass index, Kg/M2 (SD, range) 25.1 (3.8, 15.4–41.2) 
Avg. late life body mass index, Kg/M2 (SD, range), n = 588 26.7 (4.3, 16.7–43.7 
** Supplemental estrogen, n (%)  
No 315 (89.0) 
Yes  39 (11.0) 
Dietary restriction, n (%)  
No 345 (57.9) 
Yes 251 (42.1) 
APOE allele status, n (%)  
e2+ 61 (10.2) 
e3 406 (68.1) 
e4+ 129 (21.6) 
Avg. number of cholesterol measures (range, SD)  
Total cholesterol 14.4 (4.0–19.0, 2.5) 
HDL cholesterol 5.1 (2.0–10.0, 1.8) 
Notes: Midlife and late life were the 1st and 15th examinations, respectively; * The average age in which 
subjects first reported using cholesterol-lowering medications; ** Supplemental estrogen use was 
assessed in only women. 
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Table 3. EDF and adjusted R2 for trajectories of total, HDL, and total: HDL cholesterol 
ratio stratified according to APOE allele status. 
Model 
Total Cholesterol HDL Cholesterol Total: HDL Cholesterol 
EDF Adjusted R2 EDF Adjusted R2 EDF Adjusted R2 
Unadjusted model  0.12  0.01  0.06 
e2+ 4.9  1.0  3.8  
e3 7.7  3.6  4.4  
e4+ 5.7  2.8  3.3  
Adjusted model  0.22  0.19  0.20 
e2+ 4.9  1.0  3.7  
e3 7.5  3.7  4.7  
e4+ 5.6  2.9  3.3  
Notes: Unadjusted model only included APOE allele status (n = 596); Adjusted model controlled 
for the effects of age, gender, educational attainment, smoking status, systolic and diastolic blood 
pressure, blood sugar, restricted diet, body mass index, and use of cholesterol-lowering 
medications (n = 555); Abbreviations: EDF = effective degrees of freedom; HDL = high density 
lipoprotein; APOE = apolipoprotein E. 
In general, APOE e2+ subjects had higher HDL cholesterol levels compared to APOE e3 and APOE 
e4+ subjects (Figure 1). APOE e2+ subjects displayed a gradual increase in HDL cholesterol from 
midlife through late life, whereas HDL cholesterol declined until approximately 75 years of age,  
which was followed by an increase in HDL cholesterol, for APOE e3 and APOE e4+ subjects.  
The greatest difference in HDL cholesterol between APOE e2+, e3, and e4+ subjects was observed 
between 75 and 80 years of age. A mixed-effects regression model that included linear, quadratic,  
and cubic terms for age did not detect any statistically significant differences in these polynomial 
terms according to APOE allele status. However, the linear (F-value = 6.6, p = 0.01) and cubic  
(F-value = 21.1, p < 0.01) main effect polynomial terms were statistically significant. 
All subjects maintained consistent total: HDL cholesterol ratio until 70 years of age when the 
trajectories began to decline (Figure 1). APOE e2+ subjects maintained significantly lower total:  
HDL ratios from midlife through late life compared to APOE e3 and APOE e4+ subjects and these 
differences increased with advancing age. There were little to no differences in the trajectories of total: 
HDL cholesterol ratio according to APOE allele status. A mixed-effects model that included linear 
through quartic polynomial terms for age and interactions with APOE allele status detected a 
statistically significant interaction between age and APOE allele status (F-value = 3.2, p = 0.04).  
The respective interactions between APOE allele status and the other three polynomial terms were not 
statistically significant.  
3.3. Cholesterol Trajectories according to Use of Cholesterol-Lowering Medications 
The trajectories of serum cholesterol levels stratified according to use of cholesterol-lowering 
medications are presented in the first row of Figure 2. In general, subjects who had a history of taking 
cholesterol-lowering medications had higher serum total cholesterol levels, lower HDL cholesterol 
levels, and higher total: HDL cholesterol ratios from midlife through late life compared to subjects 
who did not have a history of taking cholesterol-lowering medications. Subjects who had a history of 
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using cholesterol-lowering medications had similar EDF values for total cholesterol, HDL cholesterol, 
and total: HDL cholesterol ratio compared to non-medication users (Table 4). Medication users 
maintained higher total cholesterol from midlife through 80 years of age, but these subjects had a 
greater decline in total cholesterol following 60 years of age compared to non-medication users.  
These apparent differences in the trajectories of serum total cholesterol are consistent with the results 
of a mixed-effects model that included linear through 7th order polynomial terms for age. This model 
detected statistically significant differences in the APOE allele status by linear (F-value = 22.2,  
p < 0.01), quadratic (F-value, p = 0.04), and cubic (F-value = 4.7, p < 0.03) interaction terms.  
Medication users had higher HDL cholesterol levels during midlife compared to non-medication 
users. Medication users, however, did have a slight decline in HDL cholesterol until 80 years of age, 
whereas non-medication users displayed a gradual increase until 60 years of age, which was followed 
by a slight decline. Both medication users and non-users exhibited an increase in HDL cholesterol 
levels following 80 years of age. These findings are supported by the results of a mixed-effects 
regression model that included linear, quadratic, and cubic polynomial terms for age. There were 
significant linear (F-value = 6.7, p = 0.01) and cubic trends (F-value = 21.1, p < 0.01) in HDL 
cholesterol according to age for all subjects, but only the APOE allele status by age interaction term 
was statistically significant (F-value = 7.9, p = 0.01).  
Finally, subjects with a history of using cholesterol-lowering medications maintained significantly 
higher total: HDL cholesterol ratio compared to non-medication users from midlife through late life 
(row 1, Figure 2). However, medication users did have a greater decline in total: HDL cholesterol ratio 
following 70 years of age. This is supported by the findings of a mixed-effects regression model that 
included linear, quadratic, and cubic polynomial terms for age. In this model the age2 by APOE allele 
status interaction term was statistically significant (F-value = 7.6, p = 0.01). 
The second row of Figure 2 presents cholesterol trajectories according to APOE allele status 
adjusting for the effects of age of first using cholesterol-lowering medications. APOE e2+, e3,  
and e4+ subjects had similar trajectories of serum total cholesterol through 50 years of age.  
Total cholesterol continued to increase among APOE e4+ subjects until 60 years of age, whereas total 
cholesterol began to decline at 50 years of age for APOE e3 and APOE e2+ subjects. The EDF values 
for the smooth terms were similar for APOE e4+, e3, and e2+ subjects (Table 3). However, a mixed-effects 
model that included linear through quartic polynomial terms for age detected statistically significant 
differences in the quadratic (F-value = 3.3, p = 0.04) and quartic (F-value = 9.6, p < 0.01) polynomial 
terms according to APOE allele status while the cubic interaction term approached statistical 
significance (F-value = 2.5, p = 0.08). 
APOE e4+ had significantly higher HDL cholesterol levels during midlife compared to APOE e3 
and APOE e2+ subjects (row two, Figure 2). APOE e4+ subjects, however, did exhibit the greatest 
decline in HDL cholesterol with age. According to the EDF values for the smooth terms APOE e4+ 
and APOE e2+ subjects displayed linear declines in HDL cholesterol, whereas the trajectory of HDL 
cholesterol for APOE e3 subjects showed a slight quadratic trend (Table 4). There was considerable 
overlap in the 95% confidence intervals for the estimated values of HDL cholesterol, which suggests 
there is not a significant difference in the trajectories of HDL cholesterol according to APOE allele 
status. This is supported by the results of a mixed-effects regression model that included linear and 
quadratic polynomial terms for age interactions with APOE allele status. In this model, the linear term 
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for age was statistically significant (F-value = 16.2, p < 0.01), but there was not a statistically 
significant interaction between age and APOE allele status.  
There was substantial overlap in the 95% confidence intervals for estimated values of total:  
HDL cholesterol ratio according to APOE e4 allele status (row two, Figure 2). Based on the EDF 
values for the smooth terms (Table 4), APOE e4+ and e3 subjects exhibited cubic trends in total:  
HDL cholesterol ratio. APOE e3 and APOE e4+ subjects maintained consistent total: HDL cholesterol 
ratio until 70 years of age, at which point the trajectories began to decline. The total: HDL cholesterol 
ratio trajectory for APOE e2+ subjects followed a quartic trajectory (Table 4). The ratio of total:  
HDL cholesterol increased from 45–55 years of age, decreased until 60 years of age, plateaued until  
75 years of age, and declined dramatically after 75 years of age. These visibly evident differences in 
total: HDL cholesterol ratio trajectories according to APOE allele status are supported by the results of 
a mixed-effects regression model that included linear through quartic polynomial terms for age in 
which the age4 by APOE allele status interaction was the only statistically significant interaction term 
(F-value = 3.5, p = 0.03). 
Table 4. EDF and adjusted R2 for trajectories of total, HDL, and total: HDL cholesterol 
ratio stratified according to use of cholesterol lowering medications, and APOE allele 
status adjusting for age of first using cholesterol lowering medications. 
Model 
Total Cholesterol HDL Cholesterol Total: HDL Cholesterol 
EDF Adjusted R2 EDF Adjusted R2 EDF Adjusted R2 
Use of cholesterol-lowering 
medications 
 0.22  0.19  0.16 
No 7.2  3.7  4.0  
Yes 5.4  2.5  3.7  
Adjusted model  0.26  0.28  0.20 
e2+ 3.4  1.0  3.8  
e3 4.6  1.5  3.3  
e4+ 4.6  1.0  2.6  
Notes: Model for use of cholesterol-lowering medications controlled for the effects of gender, educational 
attainment, smoking status, systolic and diastolic blood pressure, blood sugar, restricted diet, body mass index, 
and APOE allele status (n = 555). Adjusted model controlled for the effects of age, gender, educational attainment, 
smoking status, systolic and diastolic blood pressure, blood sugar, restricted diet, body mass index,  
APOE allele status, and age of first using cholesterol-lowering medications (n = 102). Abbreviations:  
EDF = effective degrees of freedom; HDL = high density lipoprotein; APOE = apolipoprotein E. 
3.4. Cholesterol Trajectories Stratified by Gender, and APOE Allele Status Adjusting for Menopause 
Cholesterol trajectories stratified according to gender are presented in the first row of Figure 3. 
During midlife, women had significantly higher total cholesterol levels compared to men, but women 
exhibited an increase in total cholesterol until 55 years of age compared to 45 years of age for men. 
The EDF values were similar for men and women, but women showed a greater decline in serum total 
cholesterol with age compared to men. These findings are supported by the results from a  
mixed-effects regression model that included linear through 7th order polynomial terms for age and 
interactions terms with APOE allele status. This model detected statistically significant differences in 
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the linear (F-value = 149.6, p < 0.01), quadratic (F-value = 35.5, p < 0.01), quartic (F-value = 43.0,  
p < 0.01), and quintic (i.e., age5; F-value = 9.3, p < 0.01) polynomial terms according to APOE  
allele status. 
Both men and women maintained consistent levels of HDL cholesterol (first row, Figure 3; Table 5). 
Women had significantly higher HDL cholesterol levels from midlife through late life compared to 
men. The estimated trajectories for HDL cholesterol and the EDF values indicate that there is a 
between group effect of sex on HDL cholesterol, but that the trajectories do not differ according to sex. 
A mixed-effects model that included linear, quadratic, and cubic polynomial terms for age along with 
interactions with APOE allele status supports this finding. There were no significant differences in any 
of the polynomial terms included in this model according to APOE allele status.  
Finally, men maintained significantly higher total: HDL cholesterol ratio compared to women from 
midlife through late life (first row, Figure 3). The EDF values for the smooth terms were very similar 
for men and women, but there is evidence for significant differences in these trajectories.  
A mixed-effects model that included linear through quartic polynomial terms for age detected 
statistically significant differences in the linear interaction term (F-value = 6.6, p = 0.01) and the 
quadratic interaction term approached statistical significance (F-value = 3.6, p = 0.06). 
Table 5. EDF and adjusted R2 for trajectories of total, HDL, and total: HDL cholesterol 
ratio according to gender, and APOE allele status adjusting for age of menopause. 
Model 
Total Cholesterol HDL Cholesterol Total: HDL Cholesterol 
EDF Adjusted R2 EDF Adjusted R2 EDF Adjusted R2 
Gender  0.25  0.19  0.20 
Male 6.2  3.0  4.5  
Female  7.3  4.2  4.3  
Adjusted   0.25  0.08  0.15 
e2+ 5.0  1.0  2.9  
e3 7.1  4.2  4.6  
e4+ 5.5  2.6  3.1  
Notes: Model for gender controlled for the effects of educational attainment, smoking history, 
average systolic and diastolic blood pressure, average blood sugar, restricted diet, average body 
mass index, use of cholesterol-lowering medications, and APOE allele status (n = 555). Adjusted 
model controlled for the effects of educational attainment, smoking, systolic and diastolic 
blood pressure, blood sugar, restricted diet, body mass index, APOE allele status, age of 
menopause, use of supplemental estrogen, and cause of cessation of menses (n = 335). 
Abbreviations: EDF = effective degrees of freedom; HDL = high density lipoprotein;  
APOE = apolipoprotein E. 
Cholesterol trajectories stratified according to APOE allele status among women adjusted for the 
effects of supplemental estrogen, age of menopause, and cause of menses cessation are presented in 
the second row of Figure 3. The EDF values for the smooth terms are provided in Table 5.  
Women who were APOE e2+ maintained significantly lower total cholesterol and total: HDL 
cholesterol ratio from midlife through late life compared to women who were APOE e4+ or APOE e3. 
However, mixed-effects models for total cholesterol, which included linear through 7th order 
polynomial terms for age, and total: HDL cholesterol ratio, which included linear through quartic 
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polynomial terms for age, did not detect statistically significant differences in these trajectories 
according to APOE allele status. All women maintained consistent levels of HDL cholesterol and there 
were little to no differences in HDL cholesterol according to APOE allele status from midlife through 
late life. These findings are consistent with those from a mixed-effect model that did not detect  
any statistically significant differences in linear through quartic polynomial terms according to  
APOE allele status.  
3.5. Cholesterol Trajectories Stratified according to Longevity 
An explanation for the observed decline in total cholesterol levels, increase in HDL cholesterol 
levels and decline in total: HDL cholesterol ratio is that subjects with healthy cholesterol levels are 
more likely to reach very old age. The majority of subjects included in the final sample lived beyond 
80 years of age (n = 460, 77.2%), which included 133 subjects who lived past 90 years of age. 
Compared to subjects who did not live beyond 80 years of age, subjects who were 80 years of age or 
older were more likely to be female (n = 290 (63.0%), n = 64 (47.1%),  = 11.1, p < 0.01),  
and less likely to have been a smoker during midlife (n = 95 (72.5%), n = 189 (42.4%),  = 37.8,  
p < 0.01) and late life (n = 57 (43.8%), n = 96 (21.1%),  = 30.7, p < 0.01).  
Since there were statistically significant differences in the characteristics of the final sample 
according to longevity, a subsequent analysis was conducted in which the trajectories of total 
cholesterol, HDL cholesterol, and total: HDL cholesterol were stratified according to longevity  
(age of death < 80 years, >80 to <90, and >90). These models adjusted for the effects of age, 
educational attainment, smoking, systolic and diastolic blood pressure, blood sugar, BMI, restricted 
diet, and use of cholesterol-lowering medications.  
The trajectories for total cholesterol, HDL cholesterol, and total: HDL cholesterol ratio are 
presented in the first row of Figure 4 and the corresponding EDF values are presented in Table 6. 
Subjects who lived beyond 90 years of age had the lowest total cholesterol levels during midlife,  
but the highest levels for total cholesterol during old age. Compared to subjects who did not live 
beyond 80 years, subjects who lived between 80 and 90 years had similar total cholesterol levels 
during midlife and slightly higher total cholesterol levels, most notably after 70 years of age.  
The serum total cholesterol trajectories according to longevity were examined further with a  
mixed-effects model that included linear through 7th order polynomial terms with age and interactions 
according to longevity status. This model detected statistically significant interactions between longevity 
and the linear (F-value = 21.7, p < 0.01), quadratic (F-value = 6.3, p < 0.01), quartic (F-value = 5.0,  
p = 0.01), and quintic (F-value = 9.2, p < 0.01) polynomial terms.  
There were little to no differences in the estimated trajectories of HDL cholesterol according to 
longevity. This is supported by the findings from a mixed-effects model that included linear, quadratic, 
and cubic polynomial terms for age and interactions with longevity status. In this model, the cubic 
polynomial term was statistically significant (F-value = 20.6, p < 0.01), but there was not a statistically 
significant interaction between age3 and longevity.  
Finally, subjects who did not live past 80 years had a linear decline in total: HDL cholesterol ratio, 
whereas total: HDL cholesterol ratio for subjects who lived past 80 and 90 years of age did not begin 
to decline until approximately 65 years of age. Interestingly, subjects who lived past 90 years of age 
had low total: HDL cholesterol ratio that increased until approximately 60 years of age. This visibly 
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apparent difference in the trajectory of total: HDL cholesterol ratio is detected in a mixed-effects 
model that included linear, quadratic, and cubic terms for age in which the interaction term between 
age2 and longevity was statistically significant (F-value = 3.0, p = 0.05).  
Table 6. EDF and adjusted R2 for trajectories of total, HDL, and total: HDL cholesterol 
ratio according to longevity, and APOE allele status among long-lived subjects. 
Model 
Total Cholesterol HDL Cholesterol Total: HDL Cholesterol 
EDF Adjusted R2 EDF Adjusted R2 EDF Adjusted R2 
Longevity  0.22  0.19  0.20 
<80 5.3  3.1  1.0  
>80 to <90 6.8  3.6  4.0  
>90  6.7  1.0  3.3  
APOE allele status  0.22  0.16  0.16 
e2+ 5.0  1.0  3.2  
e3 7.3  2.1  3.8  
e4+ 5.8  1.0  3.1  
Notes: All models controlled for the effects of age, gender, educational attainment, smoking status, 
systolic and diastolic blood pressure, blood sugar, restricted diet, body mass index, and use of 
cholesterol-lowering medications. Longevity models also controlled for the effects of APOE allele 
status; Cholesterol trajectories according to longevity (n = 585); cholesterol trajectories according 
to APOE allele status (n = 430). 
A final analysis limited to the 460 subjects who lived beyond 80 years of age (77% of final sample) 
was conducted to assess if trajectories of total cholesterol, HDL cholesterol, and total: HDL cholesterol 
ratio according to APOE allele status differed once subjects who did not live beyond 80 years were 
removed. These models adjusted for the effects of age, educational attainment, smoking history, 
average systolic and diastolic blood pressure, average blood sugar, average BMI, restricted diet, and 
use of cholesterol-lowering medications. It should be noted that APOE e3 subjects remained in the 
FHS Original Cohort longer compared to APOE e2 and APOE e4 subjects as indicated by the five 
more years of observation for APOE e3 subjects (Figure 4). There were minimal differences in the 
trajectories and EDF values of total cholesterol, HDL cholesterol, and total: HDL cholesterol ratio 
(second row, Figure 4; Table 6) compared to the trajectories and EDF values that included all subjects 
in the analysis (second row, Figure 1; Table 3). The findings from the mixed-effects models for these 
trajectories were also consistent with the models that included the entire sample. The mixed-effects 
model for total cholesterol detected statistically significant interactions between APOE allele status 
and the quadratic (F-value = 5.1, p = 0.01) and quartic (F-value = 6.6, p = 0.01) polynomial terms  
for age. As was observed in the initial analysis, there were no statistically significant interactions 
between any of the polynomial terms for age and APOE allele status in the mixed-effects model  
for HDL cholesterol. Finally, the mixed-effects model of total: HDL cholesterol for subjects who lived 
beyond 80 years of age detected a statistically significant interaction between age and APOE allele 
status (F-value = 4.2, p = 0.02), whereas the interactions between APOE allele status and other polynomial 
terms (quadratic, cubic, and quartic) were not statistically significant. This is consistent with the results 
from the mixed-effects model that included the entire final sample. To summarize, these findings provide 
evidence that the results from the initial analysis are not due to a healthy survivor bias.  
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4. Discussion 
The findings from this study present new evidence for age related changes in total cholesterol,  
HDL cholesterol, and total: HDL cholesterol ratio according to APOE allele status. Results from the 
GAMMs indicated that APOE e2+ subjects maintained lower serum total cholesterol levels,  
higher HDL cholesterol levels, and lower total: HDL cholesterol ratios from midlife through late life 
compared to APOE e3 and APOE e4+ subjects after controlling for the effects of age gender, 
educational attainment, smoking, use of cholesterol-lowering medications, systolic and diastolic blood 
pressure, blood sugar, diet restriction, and BMI. Similar findings were observed when subjects who did 
not live beyond 80 years of age were excluded. Further analysis using mixed-effects regression models 
detected statistically significant interactions between polynomial terms for age and APOE allele status 
for trajectories of serum total cholesterol. This provides evidence that trajectories of serum total 
cholesterol from midlife through late life differ according to APOE allele status. However, a mixed-effects 
regression model for HDL cholesterol did not detect any statistically significant interactions between 
APOE allele status and polynomial terms for age. This suggests that there is a between group effect for 
APOE on HDL cholesterol levels, but there are not substantial differences in HDL cholesterol 
trajectories according to APOE allele status. Finally, there was a statistically significant interaction 
between age and APOE allele status in the mixed-effects model for total: HDL cholesterol ratio,  
but the interactions between APOE allele status and quadratic, cubic, and quartic polynomial terms 
were not statistically significant. These findings, when interpreted with the results from the GAMM, 
indicate there is a significant between group effect for APOE allele status on total: HDL cholesterol 
trajectories and that APOE e2+ subjects have a greater overall decline in total: HDL cholesterol ratio 
than APOE e3 or APOE e4+ subjects.  
Prior research has focused on age-related changes to total and HDL cholesterol levels through the 
lifespan and the present analysis is the first study to our knowledge that has examined trajectories of 
serum cholesterol from midlife through late life stratified according to APOE allele status. In the 
current study, serum total cholesterol levels increased with age during midlife but declined during old 
age. These results are consistent with other studies that have examined age related changes in serum 
total cholesterol [19–22,24,25]. We observed an increase in HDL cholesterol from midlife through late 
life, but there were no statistically significant differences in HDL cholesterol trajectories according  
to APOE allele status. This increasing trend in HDL cholesterol with age as been reported  
previously [25], but other studies have observed consistent levels [22] or a decline [20] in  
HDL cholesterol with age.  
Previous studies have also assessed sex differences in serum cholesterol levels. The findings from 
the GAMM and mixed-effects models provide evidence for significant differences in the trajectories of 
serum cholesterol between men and women. Women had lower serum total cholesterol during midlife, 
but higher total cholesterol during late life compared to men. Women also had significantly higher 
HDL cholesterol and total HDL cholesterol and lower total: HDL cholesterol ratio from midlife 
through late life compared to men. These results are consistent with previous research [31,76].  
It should be noted that we chose not to stratify all analyses according to sex because sex differences in 
the trajectories of serum cholesterol levels according to APOE allele status were not the objective of 
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the present analysis. Future research should examine how sex may modify the relationship between 
APOE allele status and trajectories of serum cholesterol levels from midlife through late life. 
The decline in total cholesterol with increasing age among older adults observed in the current 
study may be the result of a survivor effect in which subjects at an increased risk for mortality due to 
diseases caused by elevated cholesterol die and subjects with healthy cholesterol levels remain in a 
study into old age [77]. In the current study, subjects who lived beyond 90 years had lower total 
cholesterol during midlife, but higher total cholesterol during late life, compared to subjects who lived 
between 80 and 90 years. Subjects who lived between 80 and 90 years had higher total cholesterol 
levels during late life compared to subjects who did not live past 80 years, but there were little to no 
differences in midlife total cholesterol levels between these two groups. There is evidence from 
previous research that a decrease in cholesterol synthesis by the liver and a decline in the amount  
of dietary cholesterol absorbed by the intestines contributes to the decline in total cholesterol later in 
life [78–80]. A survivor effect may also partially explain the increase in HDL cholesterol after  
80 years of age. Subjects who lived beyond 80 years of age were more likely to be female and less 
likely to smoke during midlife and late life. These characteristics have been associated with higher 
levels of HDL cholesterol [39] and the overall better health of subjects who lived past 80 years may 
explain the increase in HDL cholesterol among the oldest-old in the FHS Original Cohort.  
Certain limitations in this study need to be acknowledged. First, we limited the number of 
covariates included in the adjusted models by using midlife and late life values for potentially 
important covariates such as smoking status, measures for systolic and diastolic blood pressure and 
blood sugar, use of cholesterol-lowering medications, and BMI. This approach allowed us to account 
for changes in these covariates from midlife through late life, but may have oversimplified  
the relationship between these variables and trajectories of serum cholesterol levels. Furthermore,  
we controlled for the use of cholesterol-lowering medications by dichotomizing subjects as ever using 
medications (yes, no). It has been suggested that adding a constant value to observed values for 
subjects receiving treatment is more appropriate when controlling for treatment effects than including 
treatment status as a dichotomous covariate [81]. These limitations can be addressed by future research 
that focuses on how changes in specific health behaviors and health conditions through the life span 
influence trajectories of serum cholesterol from midlife through late life. A second potential limitation 
is that the FHS did not provide a definition for what constituted a restricted diet. Clinical trials indicate 
that diets rich in whole grains, fruits, nuts, and vegetables have beneficial effects on cardiovascular 
disease risk factors including high cholesterol, diabetes, and hypertension [82]. We were unable to 
assess the dietary preferences and caloric intake among subjects who reported consuming a restricted 
diet because the FHS did not introduce a detailed food history questionnaire until the 20th clinical 
examination. Only 71 subjects (11.9%) included in the final sample were still remaining in the FHS 
Original Cohort during the 20th examination and controlling for the effects of dietary preferences and 
caloric intake would have considerably reduced the sample size. Therefore, our findings need to be 
replicated using other sample populations from studies that have assessed caloric intake throughout the 
life span since older adults can experience decreased appetite [83] and malnutrition [84], which may 
contribute to a decline in cholesterol during old age. Another limitation of the present analysis is we 
did not control for potentially important factors that modify or are related to serum cholesterol levels such 
as alcohol consumption [85], physical activity [86], cardiovascular diseases [87], and inflammation [88]. 
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Additional research on the effects that these variables, as well as other genetic, biological, lifestyle, 
and sociocultural factors, have on serum cholesterol levels through the life span is warranted.  
5. Conclusions 
In summary, this study presents evidence that serum total cholesterol and total: HDL cholesterol 
ratio trajectories from midlife through late life differ according to APOE allele status. Between-group 
differences in HDL cholesterol according to APOE allele status were also detected.  
The findings from this study have important implications to public health. First, we observed that 
adults who lived past 90 years of age had higher total cholesterol during late life compared to adults 
who did not live past 80 or 90 years of age. This has potentially important implications for the 
treatment of high cholesterol with statins and other cholesterol-lowering medications because these 
findings suggest that higher cholesterol may be associated with longevity. An argument can be made 
that it may be harmful to prescribe older adults statins or other medications to lower cholesterol based 
on evidence that low serum cholesterol and a decline in serum cholesterol are associated with 
increased mortality [89,90]. However, it is not clear if a decline in cholesterol plays a causal role in 
mortality or this decline is a consequence of changes to systems involved in cholesterol homeostasis, 
such as liver function, cholesterol metabolism, and appetite, that are negatively affected by biological 
changes that occur during the period of terminal decline prior to death [91]. Second, the APOE e4 
allele is associated with an increased risk for several aging related diseases, including AD [54] and 
cardiovascular diseases [92], whereas the APOE e2 allele has been associated with a decreased risk for 
these diseases [55]. To efficiently modify cholesterol, and as a result, disease risk, it is necessary to 
take into account APOE allele status and how APOE allele status influences serum cholesterol levels 
from midlife through late life. A plausible hypothesis is that the increased risk for cognitive and 
vascular diseases among older adults who carry one or more APOE e4 alleles may be due, in part,  
to higher total cholesterol and lower HDL cholesterol from midlife through late life, whereas the 
decreased risk for these diseases associated with the APOE e2 allele may be due to the lower total 
cholesterol and higher HDL cholesterol across the life span. This hypothesis is based on interpreting 
the findings of the present analysis within the context of findings from previous research. Additional 
research is necessary to determine if reducing total cholesterol and increasing HDL cholesterol 
decreases the risk for cognitive and vascular diseases among adults who carry one or more  
APOE e4 alleles. 
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